Cargando…

Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort

BACKGROUND: Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction (GEJ) cancer could be demonstrated in predominantly Asian cohorts, whereas data in Western patients outside of clinical trials are vastly missing. METHODS: In this multi-institutional ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlintl, Verena, Huemer, Florian, Rinnerthaler, Gabriel, Melchardt, Thomas, Winder, Thomas, Reimann, Patrick, Riedl, Jakob, Amann, Arno, Eisterer, Wolfgang, Romeder, Franz, Piringer, Gudrun, Ilhan-Mutlu, Aysegül, Wöll, Ewald, Greil, Richard, Weiss, Lukas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744304/ https://www.ncbi.nlm.nih.gov/pubmed/35012477 http://dx.doi.org/10.1186/s12885-021-09115-6

Ejemplares similares

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
por: Huemer, Florian, et al.
Publicado: (2020)

Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry
por: Huemer, Florian, et al.
Publicado: (2020)

Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
por: Huemer, Florian, et al.
Publicado: (2022)

Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature
por: Heregger, R., et al.
Publicado: (2021)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
por: Huemer, Florian, et al.
Publicado: (2018)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
por: Magnes, Teresa, et al.
Publicado: (2021)

Coexistence of Primary GEJ Adenocarcinoma and Pedunculated Gastric Gastrointestinal Stromal Tumor
por: Alkaaki, Aroub, et al.
Publicado: (2018)

Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma – an Austrian expert consensus statement
por: Taghizadeh, Hossein, et al.
Publicado: (2023)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

GEJ cancers: gastric or esophageal tumors? searching for the answer according to molecular identity
por: Barra, Williams Fernandes, et al.
Publicado: (2017)

Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
por: Huemer, Florian, et al.
Publicado: (2020)

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study
por: Piringer, Gudrun, et al.
Publicado: (2023)

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence
por: Magnes, T., et al.
Publicado: (2021)

Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
por: Scheithauer, Werner, et al.
Publicado: (2019)

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
por: Rinnerthaler, Gabriel, et al.
Publicado: (2020)

Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies
por: Magnes, Teresa, et al.
Publicado: (2021)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics
por: Huemer, F, et al.
Publicado: (2019)

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
por: Adashek, Jacob J., et al.
Publicado: (2020)

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
por: Huemer, Florian, et al.
Publicado: (2021)

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia: A case report
por: Huemer, Florian, et al.
Publicado: (2016)

C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients
por: Schlick, Konstantin, et al.
Publicado: (2019)

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study
por: Riedl, Jakob Michael, et al.
Publicado: (2020)

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
por: Fuchs, Charles S, et al.
Publicado: (2016)

Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach—A Real World Data Analysis
por: Hempel, Louisa, et al.
Publicado: (2021)

Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017
por: Magnes, Teresa, et al.
Publicado: (2017)

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
por: Magnes, T., et al.
Publicado: (2019)

How I treat diffuse large B-cell lymphoma
por: Melchardt, T., et al.
Publicado: (2023)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

New emerging targets in cancer immunotherapy: the role of LAG3
por: Puhr, Hannah Christina, et al.
Publicado: (2019)

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
por: Melchardt, Thomas, et al.
Publicado: (2016)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
por: Schlick, Konstantin, et al.
Publicado: (2020)

Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study
por: Lang, David, et al.
Publicado: (2021)

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer
por: Huemer, Florian, et al.
Publicado: (2015)

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial
por: Westphal, Theresa, et al.
Publicado: (2018)

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2021)

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
por: Sun, Weijing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ccfgcstp8rdcp79968n2f6jivj